Compare CSGS & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CSGS | AUPH |
|---|---|---|
| Founded | 1994 | 1993 |
| Country | United States | Canada |
| Employees | N/A | 128 |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 1.9B |
| IPO Year | 1996 | 2014 |
| Metric | CSGS | AUPH |
|---|---|---|
| Price | $80.07 | $14.24 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 6 | 4 |
| Target Price | ★ $72.43 | $17.25 |
| AVG Volume (30 Days) | 299.2K | ★ 973.0K |
| Earning Date | 05-06-2026 | 05-11-2026 |
| Dividend Yield | ★ 1.70% | N/A |
| EPS Growth | N/A | ★ 5075.00 |
| EPS | 1.98 | ★ 2.07 |
| Revenue | ★ $996,810,000.00 | $283,055,000.00 |
| Revenue This Year | $5.45 | $16.53 |
| Revenue Next Year | $3.02 | $16.24 |
| P/E Ratio | $40.35 | ★ $6.75 |
| Revenue Growth | 13.91 | ★ 20.38 |
| 52 Week Low | $54.65 | $6.83 |
| 52 Week High | $80.67 | $16.54 |
| Indicator | CSGS | AUPH |
|---|---|---|
| Relative Strength Index (RSI) | 55.56 | 47.76 |
| Support Level | $79.41 | $13.52 |
| Resistance Level | $80.22 | $15.23 |
| Average True Range (ATR) | 0.25 | 0.47 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 57.65 | 28.32 |
CSG Systems International Inc is a purpose-driven, SaaS platform company that enables companies in a wide variety of industry verticals to tackle the growing complexity of business in the digital age. The company's cloud-first architecture and customer-centric approach empower companies to deliver unforgettable experiences for B2B (business-to-business), B2C (business-to-consumer), and B2B2X (business-to-business-to-consumer) customers, making it easier for people and businesses to connect to, use and pay for the services the company offers. The company operates in one segment i.e. Solutions and Services. Geographically, it generates revenue from the United States.
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.